Please login to the form below
Akcea Pharma
This page shows the latest Akcea Pharma news and features for those working in and with pharma, biotech and healthcare.
Pfizer pays $250m upfront to Akcea for phase 2 antisense drug
affiliate. The big pharma – which has traditionally relied on acquisitions and licensing deals to keep its pipeline stocked – is paying $250m upfront for rights to AKCEA-ANGPTL3-LRx, an antisense oligonucleotide ... The Swiss pharma group took an
Latest news
-
Akcea gets first OK for Waylivra in rare triglyceride disorder
EU becomes the first market for the new drug. Akcea has been granted a conditional approval for Waylivra, its antisense drug for rare inherited disorder familial chylomicronemia syndrome (FCS), in Europe. ... In Europe, Akcea has committed to a
-
Akcea steals march on Alnylam with NICE approval
Advantage to Tegsedi over Onpattro. NICE has recommended Akcea Therapeutics’ rare disease treatment Tegsedi (inotersen), after the company improved its price offer. ... Richard A. Jones, SVP Head of Europe for Akcea Therapeutics. “hATTR amyloidosis
-
Despite FDA concerns, Akcea rare disease drug clears FDA panel
FDA now set to deliver final verdict by 30 August. Akcea Pharma has moved a step closer to commercialising Waylivra, a drug for rare disorder familial chylomicronemia syndrome (FCS), after an ... We believe that these results provide strong support to
-
Novartis boosts cardiovascular pipeline with $1bn Ionis deal
The new agreement with Ionis subsidiary Akcea Pharma gives Novartis an option to license the two lipoprotein-targeting drugs, which are in early-stage clinical development. ... Novartis is also expected to make a further equity investment of $50m in the
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- ONS data reveals significant decrease in COVID-19 antibodies
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Eli Lilly to make bebtelovimab commercially available to US states from August
- ONS records a continued fall in UK COVID-19 infections
- Engaging KOLs and Gaining Insights in Pharma's New Normal
- That ‘don’t’ impress me much
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
PMHub
IGNIFI
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...
Latest intelligence
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
- How the Royal Society’s EiR programme can help to drive UK innovation
- ...
